$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

$ino Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000105572619000029 Filed on May 09, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$2.830M	$1.530M
YoY Change	85.0%	-85.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.980M	$9.700M
YoY Change	-28.04%	24.84%
% of Gross Profit
Research & Development	$24.39M	$24.58M
YoY Change	-0.76%	0.14%
% of Gross Profit
Depreciation & Amortization	$930.9K	$897.7K
YoY Change	3.7%	71.88%
% of Gross Profit
Operating Expenses	$31.36M	$34.28M
YoY Change	-8.49%	6.08%
Operating Profit	-$28.54M	-$32.75M
YoY Change	-12.86%	49.29%
Interest Expense	$656.2K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$35.84K
YoY Change
Pretax Income	-$29.35M	-$30.18M
YoY Change	-2.75%	30.73%
Income Tax	-$62.80K	$2.170M
% Of Pretax Income
Net Earnings	-$29.22M	-$32.35M
YoY Change	-9.68%	40.13%
Net Earnings / Revenue	-1032.52%	-2114.93%
Basic Earnings Per Share	-$0.30	-$0.36
Diluted Earnings Per Share	-$0.30	-$0.36
COMMON SHARES
Basic Shares Outstanding	97.64M shares	90.45M shares
Diluted Shares Outstanding		90.45M shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.0M	$116.1M
YoY Change	10.27%	29.4%
Cash & Equivalents	$20.78M	$37.51M
Short-Term Investments	$107.2M	$78.57M
Other Short-Term Assets	$2.800M	$3.700M
YoY Change	-24.32%	-38.33%
Inventory
Prepaid Expenses
Receivables	$2.783M	$5.148M
Other Receivables	$1.300M	$2.300M
Total Short-Term Assets	$134.9M	$123.8M
YoY Change	8.94%	15.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.19M	$17.49M
YoY Change	-13.15%	78.37%
Goodwill	$10.51M	$10.51M
YoY Change	0.0%	0.0%
Intangibles	$4.494M	$5.606M
YoY Change	-19.84%	-22.38%
Long-Term Investments	$8.700M	$13.80M
YoY Change	-36.96%	-21.14%
Other Assets	$2.981M	$2.449M
YoY Change	21.75%	60.55%
Total Long-Term Assets	$56.26M	$49.83M
YoY Change	12.91%	7.08%
TOTAL ASSETS
Total Short-Term Assets	$134.9M	$123.8M
Total Long-Term Assets	$56.26M	$49.83M
Total Assets	$191.2M	$173.7M
YoY Change	10.08%	13.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.00M	$17.10M
YoY Change	-0.58%	14.0%
Accrued Expenses	$7.159M	$8.429M
YoY Change	-15.06%	42.62%
Deferred Revenue	$110.7K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.42M	$51.38M
YoY Change	-46.64%	28.43%
LONG-TERM LIABILITIES
Long-Term Debt	$60.60M	$0.00
YoY Change
Other Long-Term Liabilities	$64.26K	$9.200M
YoY Change	-99.3%	27.78%
Total Long-Term Liabilities	$64.26K	$9.200M
YoY Change	-99.3%	27.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.42M	$51.38M
Total Long-Term Liabilities	$64.26K	$9.200M
Total Liabilities	$110.2M	$60.57M
YoY Change	81.94%	27.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$649.6M	-$523.1M
YoY Change	24.19%	14.16%
Common Stock	$97.93K	$90.71K
YoY Change	7.97%	21.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$77.91M	$113.0M
YoY Change
Total Liabilities & Shareholders Equity	$191.2M	$173.7M
YoY Change	10.08%	13.27%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$29.22M	-$32.35M
YoY Change	-9.68%	40.13%
Depreciation, Depletion And Amortization	$930.9K	$897.7K
YoY Change	3.7%	71.88%
Cash From Operating Activities	-$32.45M	-$12.58M
YoY Change	158.08%	-17.42%
INVESTING ACTIVITIES
Capital Expenditures	$658.7K	$1.153M
YoY Change	-42.89%	46.15%
Acquisitions
YoY Change
Other Investing Activities	-$48.68M	$27.96M
YoY Change	-274.11%	47.47%
Cash From Investing Activities	-$49.34M	$26.80M
YoY Change	-284.07%	47.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$907.3K	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$78.88M	-$506.4K
YoY Change	-15675.93%	-161.28%
NET CHANGE
Cash From Operating Activities	-$32.45M	-$12.58M
Cash From Investing Activities	-$49.34M	$26.80M
Cash From Financing Activities	$78.88M	-$506.4K
Net Change In Cash	-$2.914M	$13.72M
YoY Change	-121.24%	264.3%
FREE CASH FLOW
Cash From Operating Activities	-$32.45M	-$12.58M
Capital Expenditures	$658.7K	$1.153M
Free Cash Flow	-$33.11M	-$13.73M
YoY Change	141.2%	-14.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001055726
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98033840	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	INOVIO PHARMACEUTICALS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q1	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-127841	USD
CY2019Q1	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	0	USD
CY2018Q1	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	127841	USD
CY2019Q1	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	0	USD
CY2018Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	2380423	USD
CY2019Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-750103	USD
CY2018Q4	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	4165848	USD
CY2019Q1	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	1279005	USD
CY2018Q4	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	27083	USD
CY2019Q1	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	14583	USD
CY2018Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	33575	USD
CY2019Q1	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	2325	USD
CY2018Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	35231244	USD
CY2019Q1	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	35231244	USD
CY2018Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	15273516	USD
CY2019Q1	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	15006953	USD
CY2018Q1	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-117943	USD
CY2019Q1	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-31250	USD
CY2018Q1	ino	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet	-87007	USD
CY2019Q1	ino	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet	-136388	USD
CY2018Q1	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-171026	USD
CY2019Q1	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	320741	USD
CY2018Q1	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	0	USD
CY2019Q1	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	-2886843	USD
CY2019Q1	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	-12500	USD
CY2018Q1	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	0	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	134902998	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5671764	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7159243	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	87814824	USD
CY2018Q1	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	55522	USD
CY2019Q1	ino	Interest Income Accrued On Short Term Investments Certificates Of Deposit InterestIncomeAccruedOnShortTermInvestmentsCertificatesOfDeposit	1908	USD
CY2018Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1120805	USD
CY2019Q1	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1441546	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23134733	USD
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	15644783	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3316361	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2783264	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	738583	USD
CY2019Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1295737	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-528867	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	290310	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	707794215	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	727166934	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	15752698	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3575750	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3432796	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	404000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	404062	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	266563	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	267000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11551910	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27341837	shares
CY2018Q4	us-gaap	Assets Assets	131113265	USD
CY2019Q1	us-gaap	Assets Assets	191165508	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	539546	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	528736	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31442	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58067588	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	106708394	USD
CY2015Q2	us-gaap	Available For Sale Equity Securities Amortized Cost Basis AvailableForSaleEquitySecuritiesAmortizedCostBasis	0	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	57538852	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	107216498	USD
CY2019Q1	us-gaap	Capital Capital	107500000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23693633	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20779152	USD
CY2019Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	128000000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23786579	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37508863	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2914481	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13722284	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23693633	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20779152	USD
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97934010	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97225810	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97934010	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	97226	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	97934	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32463593	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28400085	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-69605	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-32463593	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-28469690	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	223577	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	110694	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	150793	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	141803	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	652000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	179000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	31000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	3	investment
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	24766	USD
CY2019Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	24766	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1065387	USD
CY2019Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8518207	USD
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q1	us-gaap	Depreciation Depreciation	897709	USD
CY2019Q1	us-gaap	Depreciation Depreciation	930907	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	977792	USD
CY2019Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1315610	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7300000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M0D
CY2018Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3023987	USD
CY2019Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2225427	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19957728	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	20224291	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1900000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	800000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	276000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	493000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	520000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	547000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24717873	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24717873	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4760145	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4493582	USD
CY2018Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-253316	USD
CY2019Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-35839	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9698015	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6975029	USD
CY2018Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2019Q1	us-gaap	Goodwill Goodwill	10513371	USD
CY2018Q4	us-gaap	Goodwill Gross GoodwillGross	10513371	USD
CY2019Q1	us-gaap	Goodwill Gross GoodwillGross	10513371	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30181017	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29351667	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2169811	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-62800	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6363762	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6999110	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	371798	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	337818	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-855354	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-533097	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	1755950	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	557154	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-183011	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1487479	USD
CY2018Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	22900404	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-121873	USD
CY2018Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	164288	USD
CY2019Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	68806	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-190726	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	311272	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	261325	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-23076	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-598891	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19789	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4760145	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4493582	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	656248	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	312523	USD
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-66552	USD
CY2018Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	6381926	USD
CY2019Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	6430383	USD
CY2018Q1	us-gaap	Lease Cost LeaseCost	689000	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	818000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	34758000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	15952000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35299759	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	27415047	USD
CY2018Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	60562503	USD
CY2019Q1	us-gaap	Long Term Investments LongTermInvestments	8700000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	96269	USD
CY2018Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2019Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-69605	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	4023000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4052000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3979000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3891000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2861000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10878000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	44080858	USD
CY2019Q1	us-gaap	Liabilities Liabilities	110199257	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131113265	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	191165508	USD
CY2019Q1	us-gaap	Minority Interest MinorityInterest	3056771	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-506403	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78876993	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26803887	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49337127	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12575200	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32454347	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-32350828	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-29219262	USD
CY2019Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3030107	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	34275766	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	31364917	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32746122	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28535012	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	23880000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1889000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1888804	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1733600	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21990881	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21991000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22484763	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14432479	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14634769	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y11M
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2669998	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2981270	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	819177	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87333	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-217820	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-112765	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	64257	USD
CY2018Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings	253000	USD
CY2019Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings	36000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	506403	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	719397	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1153465	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	658731	USD
CY2018Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9568082	USD
CY2019Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	65198491	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1406590	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1386801	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	907330	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	75658953	USD
CY2018Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2019Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3030107	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	37525434	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	16520095	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-32350828	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-29288867	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15949014	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15185998	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24577751	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24389888	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-620426436	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-649645698	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1529644	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2829905	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3575750	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3432796	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.19
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	57538852	USD
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	107216498	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	907330	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-506403	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-719397	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	86936138	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	77909480	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142488809	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	113094563	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87032407	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80966251	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90451791	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97494968	shares
CY2019Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-bottom:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Operations</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the “Company” or “Inovio”), is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancers and infectious diseases. The Company's DNA-based immunotherapies and vaccines, in combination with its proprietary, efficacy-enabling delivery devices, are intended to generate robust immune responses, in particular functional CD8+ killer T cells and antibodies, to fight target diseases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio’s synthetic products are based on its SynCon® immunotherapy design. The Company and its collaborators are currently conducting or planning clinical programs of its proprietary SynCon® immunotherapies for HPV-caused pre-cancers, including cervical, vulvar, and anal dysplasia; HPV-caused cancers, including head & neck, cervical, anal, penile, vulvar, and vaginal; bladder cancer; glioblastoma multiforme ("GBM"); hepatitis B virus; hepatitis C virus; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; and Zika virus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's partners and collaborators include AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., ApolloBio Corporation, GeneOne Life Science Inc. ("GeneOne"), The Bill and Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (“CEPI”), Parker Institute for Cancer Immunotherapy, Defense Advanced Research Projects Agency (“DARPA”), National Institutes of Health ("NIH"), National Institute of Allergy and Infectious Diseases (“NIAID”), National Cancer Institute ("NCI"), HIV Vaccines Trial Network ("HVTN"), Walter Reed Army Institute of Research, The Wistar Institute, and the University of Pennsylvania. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</font></div></div>

Files In Submission

Name	View Source	Status
0001055726-19-000029-index-headers.html	Edgar Link	pending
0001055726-19-000029-index.html	Edgar Link	pending
0001055726-19-000029.txt	Edgar Link	pending
0001055726-19-000029-xbrl.zip	Edgar Link	pending
exhibit101.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ino-20190331.xml	Edgar Link	completed
ino-20190331.xsd	Edgar Link	pending
ino-20190331_cal.xml	Edgar Link	unprocessable
ino-20190331_def.xml	Edgar Link	unprocessable
ino-20190331_lab.xml	Edgar Link	unprocessable
ino-20190331_pre.xml	Edgar Link	unprocessable
ino-33119x10q.htm	Edgar Link	pending
ino-33119x10qex311.htm	Edgar Link	pending
ino-33119x10qex312.htm	Edgar Link	pending
ino-33119x10qex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

2019 Q1 Form 10-Q Financial Statement

#000105572619000029 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO INOVIO PHARMACEUTICALS, INC. Stock $ino

2019 Q1 Form 10-Q Financial Statement

#000105572619000029 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino